Published in Cancer Res on March 02, 2010
Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother Pharmacol (2012) 1.57
Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res (2014) 1.21
Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability. Mol Cancer Ther (2010) 1.19
Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep (2015) 1.03
The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia. Clin Cancer Res (2013) 0.94
Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1). Cell Death Dis (2014) 0.93
Current ADC Linker Chemistry. Pharm Res (2015) 0.92
Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components. Toxins (Basel) (2011) 0.87
Field Guide to Challenges and Opportunities in Antibody-Drug Conjugates for Chemists. Bioconjug Chem (2015) 0.85
Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug Conjugates. Pharm Res (2014) 0.84
Trastuzumab emtansine and stereotactic radiosurgery: an unexpected increase in clinically significant brain edema. Neuro Oncol (2014) 0.83
Antibody-DM1 conjugates as cancer therapeutics. Cancer Lett (2011) 0.83
Flow cytometry-assisted Monte Carlo simulation predicts clonogenic survival of cell populations with lognormal distributions of radiopharmaceuticals and anticancer drugs. Int J Radiat Biol (2011) 0.79
Construction and characterization of novel, completely human serine protease therapeutics targeting Her2/neu. Mol Cancer Ther (2013) 0.78
Orthogonal Cysteine Protection Enables Homogeneous Multi-Drug Antibody-Drug Conjugates. Angew Chem Int Ed Engl (2016) 0.78
Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci (2016) 0.77
Single molecular weight discrete PEG compounds: emerging roles in molecular diagnostics, imaging and therapeutics. Expert Rev Mol Diagn (2013) 0.76
Antibody Drug Conjugates: Preclinical Considerations. AAPS J (2015) 0.75
Preclinical studies of a Pro-antibody-drug conjugate designed to selectively target EGFR-overexpressing tumors with improved therapeutic efficacy. MAbs (2016) 0.75
Multivalent peptidic linker enables identification of preferred sites of conjugation for a potent thialanstatin antibody drug conjugate. PLoS One (2017) 0.75
Antibody-Drug Conjugates for Cancer Therapy. Biomedicines (2016) 0.75
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res (2008) 5.34
RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature (2010) 3.66
Chimeras of two isoprenoid synthases catalyze all four coupling reactions in isoprenoid biosynthesis. Science (2007) 2.65
The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res (2009) 2.25
An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res (2003) 2.12
Antibody-drug conjugates: an emerging concept in cancer therapy. Angew Chem Int Ed Engl (2014) 2.01
Cytomegalovirus cell death suppressor vMIA blocks Bax- but not Bak-mediated apoptosis by binding and sequestering Bax at mitochondria. Proc Natl Acad Sci U S A (2004) 1.85
Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res (2006) 1.67
Intimate partner violence during pregnancy: analysis of prevalence data from 19 countries. Reprod Health Matters (2010) 1.61
A clinically relevant SCID-hu in vivo model of human multiple myeloma. Blood (2005) 1.60
Processing of human cytomegalovirus UL37 mutant glycoproteins in the endoplasmic reticulum lumen prior to mitochondrial importation. J Virol (2006) 1.58
A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies. Blood (2013) 1.56
Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res (2011) 1.53
An anti-apoptotic viral protein that recruits Bax to mitochondria. J Biol Chem (2004) 1.49
Communication skills training for oncology professionals. J Clin Oncol (2012) 1.40
Bone sialoprotein mediates the tumor cell-targeted prometastatic activity of transforming growth factor beta in a mouse model of breast cancer. Cancer Res (2006) 1.35
Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. Blood (2004) 1.31
Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res (2006) 1.30
Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem (2006) 1.29
Cytopathic effects of the cytomegalovirus-encoded apoptosis inhibitory protein vMIA. J Cell Biol (2006) 1.28
Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. J Clin Oncol (2003) 1.21
Cell killing by antibody-drug conjugates. Cancer Lett (2007) 1.19
A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide. Exp Eye Res (2005) 1.18
Transport barriers in transscleral drug delivery for retinal diseases. Ophthalmic Res (2007) 1.17
Controlled drug release from an ocular implant: an evaluation using dynamic three-dimensional magnetic resonance imaging. Invest Ophthalmol Vis Sci (2004) 1.17
Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer. J Med Chem (2014) 1.16
Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules. Mol Cancer Ther (2010) 1.16
The isolation and characterization of renal cancer initiating cells from human Wilms' tumour xenografts unveils new therapeutic targets. EMBO Mol Med (2012) 1.15
Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer. Cancer Res (2006) 1.15
Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate. Cancer Res (2002) 1.15
SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies. Clin Cancer Res (2011) 1.14
Enzymes encoded by the farnesyl diphosphate synthase gene family in the Big Sagebrush Artemisia tridentata ssp. spiciformis. J Biol Chem (2003) 1.11
A cytoskeleton-based functional genetic screen identifies Bcl-xL as an enhancer of metastasis, but not primary tumor growth. Oncogene (2004) 1.11
Safety and pharmacokinetics of a preservative-free triamcinolone acetonide formulation for intravitreal administration. Retina (2006) 1.08
The neutralization properties of a HIV-specific antibody are markedly altered by glycosylation events outside the antigen-binding domain. J Immunol (2007) 1.06
The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates. Mol Cancer Ther (2012) 1.03
Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. Bioconjug Chem (2010) 1.03
Assessment of subconjunctival and intrascleral drug delivery to the posterior segment using dynamic contrast-enhanced magnetic resonance imaging. Invest Ophthalmol Vis Sci (2007) 1.02
Mutation of the murine Bloom's syndrome gene produces global genome destabilization. Mol Cell Biol (2006) 1.01
Tumor-specific novel taxoid-monoclonal antibody conjugates. J Med Chem (2002) 1.01
Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates. J Med Chem (2011) 1.01
Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage. Bioconjug Chem (2011) 1.01
Targeting of insulin-like growth factor-I receptor with a monoclonal antibody inhibits growth of hepatic metastases from human colon carcinoma in mice. Ann Surg Oncol (2007) 0.97
A common mechanism for branching, cyclopropanation, and cyclobutanation reactions in the isoprenoid biosynthetic pathway. J Am Chem Soc (2008) 0.96
Drug elimination kinetics following subconjunctival injection using dynamic contrast-enhanced magnetic resonance imaging. Pharm Res (2007) 0.91
Study of ocular transport of drugs released from an intravitreal implant using magnetic resonance imaging. Ann Biomed Eng (2005) 0.90
Folate receptor-specific antitumor activity of EC131, a folate-maytansinoid conjugate. Cancer Res (2007) 0.89
The pharmacokinetics of rituximab following an intravitreal injection. Exp Eye Res (2005) 0.88
Synthesis of taxoids with improved cytotoxicity and solubility for use in tumor-specific delivery. J Med Chem (2004) 0.88
Mitogen-activated protein kinases regulate LSF occupancy at the human immunodeficiency virus type 1 promoter. J Virol (2005) 0.87
Dosimetry for quantitative analysis of the effects of low-dose ionizing radiation in radiation therapy patients. Radiat Res (2006) 0.87
Failure to detect dexamethasone phosphate in the local venous blood postcathodic lontophoresis in humans. J Orthop Sports Phys Ther (2002) 0.87
Leptin concentrations experience a delayed reduction after resistance exercise in men. Med Sci Sports Exerc (2002) 0.86
Labeling of antibodies by in situ modification of thiol groups generated from selenol-catalyzed reduction of native disulfide bonds. Anal Biochem (2002) 0.86
Design of antibody-maytansinoid conjugates allows for efficient detoxification via liver metabolism. Bioconjug Chem (2011) 0.85
Evaluation of coupled convective-diffusive transport of drugs administered by intravitreal injection and controlled release implant. J Control Release (2005) 0.85
Dual inactivation of Hus1 and p53 in the mouse mammary gland results in accumulation of damaged cells and impaired tissue regeneration. Proc Natl Acad Sci U S A (2009) 0.84
A novel pathway for maytansinoid release from thioether linked antibody-drug conjugates (ADCs) under oxidative conditions. Chem Commun (Camb) (2011) 0.84
The murine cytomegalovirus cell death suppressor m38.5 binds Bax and blocks Bax-mediated mitochondrial outer membrane permeabilization. Apoptosis (2008) 0.84
The down low, social stigma, and risky sexual behaviors: insights from African-American men who have sex with men. J Homosex (2010) 0.83
Synthesis and biological evaluation of antibody conjugates of phosphate prodrugs of cytotoxic DNA alkylators for the targeted treatment of cancer. J Med Chem (2012) 0.83
Targeting CD56 by the maytansinoid immunoconjugate IMGN901 (huN901-DM1): a potential therapeutic modality implication against natural killer/T cell malignancy. Br J Haematol (2008) 0.83
Enantioselective inhibition of squalene synthase by aziridine analogues of presqualene diphosphate. J Org Chem (2010) 0.83
Antibody-cytotoxic agent conjugates: preparation and characterization. Methods Mol Biol (2009) 0.82
Alphav integrin-targeted immunoconjugates regress established human tumors in xenograft models. Clin Cancer Res (2007) 0.82
Hydrogen peroxide staining to visualize intracellular bacterial infections of seedling root cells. Microsc Res Tech (2014) 0.81
Mechanistic pharmacokinetic/pharmacodynamic modeling of in vivo tumor uptake, catabolism, and tumor response of trastuzumab maytansinoid conjugates. Cancer Chemother Pharmacol (2014) 0.81
Connective tissue growth factor (CTGF) expression modulates response to high glucose. PLoS One (2013) 0.81